Kazakhstan to introduce a European system for controlling medicine sales
A European system for controlling medicine sales will be introduced in Kazakhstan.
The quality of operating laboratories will be improved and an automated system for monitoring the movement of medicines from manufacturers to patients will be implemented. To control the sales of medicine and eliminate entry of counterfeit products into the market, European countries adopted resolutions on mandatory application of 2D codes on every package of manufactured products. Introduction of this system in Kazakhstan will ensure accounting and control of all sales of medicine. The principle of this system is the application of a unique code onto every medicine package and maintenance of a register of all drugs imported into the country, � Minister of Healthcare Yelzhan Birtanov said during the parliamentary hearings in the Majilis of the Parliament of the Republic of Kazakhstan On providing the population with medicines within the guaranteed volume of free medical assistance and on the state and development of the pharmaceutical industry in Kazakhstan.
According to the Minister, the development of a new procedure for preclinical and clinical research has begun. Rules for the ethical promotion of medicines will also be developed and the level of pharmaceutical awareness of the population and specialists will be constantly raised.
Y. Birtanov recalled that the Center for Rational Use of Medicines is working in Kazakhstan to obtain the necessary information about medicines, entitlement for free medicines, preventive measures and worrying symptoms for frequently occurring diseases. The National Center for examination of medicines, medical products and medical equipment is assessing the safety and quality of registered drugs and medical products, conducting preclinical trials of medicines.
The organizer of the hearings is the Majilis Committee on Social and Cultural Development.
Along with parliamentarians, the hearings see participation of members of the Government, heads of local executive bodies, representatives of large pharmaceutical enterprises, medical workers, foreign experts in the field of drug policy, representatives of non-governmental organizations and the media.
Recommendations to the Government of the Republic of Kazakhstan will be prepared following the results of the hearings.
Source: Government of the Republic of Kazakhstan